위십이지장궤양에서 Famotidine 의 효과

• Published in: The Korean journal of gastroenterology Vol. 19; no. 1; pp. 80 - 85
• Main Authors: 나용호, Yong Ho Nah, 박석, Suk Park, 김혁제, Won Sup Cho, 조원섭, Hyuk je Kim
• Format: Journal Article
• Language: Korean
• Published: 대한소화기학회 01.01.1987
• ISSN: 1598-9992

We conducted a single-blind randomized controlled study of 60 patients with endoscopically proven duodenal or gastric ulcers to study the efficacy and safety of famotidine, a new potent histamine H2-receptor antagonist, in accelerating healing and pain relief as compared with placebo. The famotidine group, comprising 16 cases of gastric ulcers and 20 cases of duoderial ulcers, received famotidine 20mg twice daily (after breakfast and befor bedtime). Pretreatment characteristics were similar in all four treatment groups. The duration of treatment was eight weeks for gastric ulcer and six weeks for duodenal ulcer. Healing was determined by endoscopy after completion of the trial. By the end of study, 87.5% of gastric ulcers and 90% of duodenal ulcers were healed in the famotidine group compared to 36% of gastric ulcers and 38% of duodenal ulcers in the placebo group, respectively. Famotidine 20mg bid was superior to placebo in healing ulcers. The time until relief of pain was significantly less for patients on famotidine than for those on placebo. Relief of ulcer pain usually occurred within the first week of famotidine treatment in gastric or duodenal ulcers. Therapy was generally well tolerated and there was few side effects with famotidine treatment. These results indicate that famotidine 20mg bid is effective and safe for the treatment of gastric or duodenal ulcer.